INTRODUmIONIn the last 15 years, our knowledge of receptor function has been advanced considerably by studies of the acetylcholine-receptor-ion-channel complex (AChR) of the neuromuscular junction. The Occurrence of nicotinic AChRs at very high densities in Torpedo and Electrophorus electric organs made this membrane receptor easily available for study. In addition, specific chemical probes for the different active sites have contributed significantly to our understanding of the morphology and function of this receptor. In the early 19709, a-bungarotoxin (a-BGT) was isolated from snake venoms and was found to bind irreversibly and specifically to the acetylcholine (ACh) recognition site on the nicotinic AChR.' The availability of such a highly selective probe allowed the isolation, purification, functional reconstitution into artificial lipid membranes, and, ultimately, cloning of the different subunits that comprise the nicotinic AChR.2" The pharmacological characterization of another class of toxins, the histrionicotoxins (HTX), isolated from skin secretions of frogs of the family Dendrobatidae,6*' disclosed an important new class of sites on the nicotinic AChR. These sites, distinct from the agonist recognition site and most likely located on the ion channel component of the AChR, are responsible for allosteric alterations or noncompetitive blockade of neuromuscular transmission. Drugs with distinct and well-
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.